These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 34935548)
1. Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis. Chen Z; Fan Y; Liu X; Shang X; Qi K; Zhang S Int J Biol Markers; 2022 Mar; 37(1):47-57. PubMed ID: 34935548 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis. Li Y; Zhu M; Zhang X; Cheng D; Ma X Drug Des Devel Ther; 2015; 9():1785-96. PubMed ID: 25848215 [TBL] [Abstract][Full Text] [Related]
3. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study. Yang XY; Zhang J; Yu XL; Zheng GF; Zhao F; Jia XJ J Cancer Res Ther; 2018; 14(Supplement):S65-S71. PubMed ID: 29578152 [TBL] [Abstract][Full Text] [Related]
4. DAPK promoter methylation status correlates with tumor metastasis and poor prognosis in patients with non-small cell lung cancer. Zhang J; Yu XL; Zheng GF; Zhao F Cancer Biomark; 2015; 15(5):609-17. PubMed ID: 26406950 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of DAPK promoter methylation in non-small-cell lung cancer: a systematic review and meta-analysis. Zhang Y; Wu J; Huang G; Xu S Cancer Manag Res; 2018; 10():6897-6904. PubMed ID: 30588095 [TBL] [Abstract][Full Text] [Related]
6. Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis. Li FF; Yang Y; Wang XL; Hong YY; Wang NF; Chen ZD Tumour Biol; 2014 Jun; 35(6):6011-20. PubMed ID: 24659425 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549 [TBL] [Abstract][Full Text] [Related]
8. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445 [TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of RARβ2, DAPK, hMLH1, p14, and p15 is associated with progression of breast cancer: A PRISMA-compliant meta-analysis. Qi M; Xiong X Medicine (Baltimore); 2018 Dec; 97(51):e13666. PubMed ID: 30572486 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis. Xu L; Lan H; Su Y; Li J; Wan J Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616 [TBL] [Abstract][Full Text] [Related]
11. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Kim YT; Lee SH; Sung SW; Kim JH Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review. Song X; Shi K; Zhou SJ; Yu DP; Liu Z; Han Y Drug Des Devel Ther; 2016; 10():1345-54. PubMed ID: 27103788 [TBL] [Abstract][Full Text] [Related]
13. Does hypermethylation of CpG island in the promoter region of the E-cadherin gene increase the risk of lung cancer? A meta-analysis. Sun Z; Liu G; Xu N Thorac Cancer; 2019 Jan; 10(1):54-59. PubMed ID: 30390382 [TBL] [Abstract][Full Text] [Related]
14. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review. Wu X; Wu G; Yao X; Hou G; Jiang F Drug Des Devel Ther; 2016; 10():699-709. PubMed ID: 26929601 [TBL] [Abstract][Full Text] [Related]
15. Association between promoter methylation of DAPK gene and HNSCC: A meta-analysis. Cai F; Xiao X; Niu X; Zhong Y PLoS One; 2017; 12(3):e0173194. PubMed ID: 28249042 [TBL] [Abstract][Full Text] [Related]
16. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma. Kontic M; Stojsic J; Jovanovic D; Bunjevacki V; Ognjanovic S; Kuriger J; Puumala S; Nelson HH Clin Lung Cancer; 2012 Jul; 13(4):297-303. PubMed ID: 22169480 [TBL] [Abstract][Full Text] [Related]
17. DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis. Dai L; Ma C; Zhang Z; Zeng S; Liu A; Tang S; Ren Q; Sun Y; Xu C PLoS One; 2016; 11(12):e0167228. PubMed ID: 27907054 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of DAPK promoter methylation in lymphoma: A meta-analysis. Wang H; Zhou LY; Guan ZB; Zeng WB; Zhou LL; Liu YN; Pan XY PLoS One; 2019; 14(1):e0210943. PubMed ID: 30682070 [TBL] [Abstract][Full Text] [Related]
19. Correlation Between RASSF1A Gene Promoter Hypermethylation in Serum or Sputum and Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis. Zhang Z; Yan S; Cui H; Chen H; Liu J Med Sci Monit; 2019 Jul; 25():5518-5524. PubMed ID: 31342946 [TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of the relationship between RARβ gene promoter methylation and non-small cell lung cancer. Hua F; Fang N; Li X; Zhu S; Zhang W; Gu J PLoS One; 2014; 9(5):e96163. PubMed ID: 24796328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]